U.S. FDA's chief medical and science officer Prasad departs agency
STAT News first reported about Prasad's departure, saying it came after a number of controversial decisions by the FDA regarding a gene therapy drug.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.